Abbott and Neurocrine Biosciences, Inc. have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids. Abbott will receive worldwide exclusive rights to develop and commercialize...